Glycoconjugate vaccines: platforms and adjuvants for directed immunity
Glycobiology · 30.09.2024 · 34 (11)
DOI: 10.1093/glycob/cwae092 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Glycobiology, online erschienen am 27.11.2024. Verfasst von Valerie Lensch und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, United States. Hauptthemen laut MEDLINE: Glycoconjugates, Vaccines, Conjugate. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Science Foundation.
Abstract (Originalsprache)
Central to immune recognition is the glycocalyx, a glycan-rich coat on all cells that plays a crucial role in interactions that enable pathogen detection and activation of immune defenses. Pathogens and cancerous cells often display distinct glycans on their surfaces, making these saccharide antigens prime targets for vaccine development. However, carbohydrates alone generally serve as poor immunogens due to their often weak binding affinities, inability to effectively recruit T cell help, and reliance on adjuvants to iboost immune activation. The introduction of glycoconjugate vaccines, initially involving the covalent coupling of carbohydrate antigens to carrier proteins, marked a pivotal advancement by facilitating neutralizing antibody production against carbohydrate targets. Despite successes in generating glycoconjugate vaccines against certain bacterial diseases, challenges persist in creating effective vaccines against numerous intracellular pathogens and non-communicable diseases such as cancer. In this review, we highlight new developments in conjugate vaccine platforms aim to overcome these limitations by optimizing the display of glycan and T cell epitopes as well as incorporating defined carbohydrate adjuvants to direct tailored immune responses. These advancements promise to improve the effectiveness of carbohydrate-based vaccines and broaden their coverage against a wide range of diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, United States.
- Koch Institute for Integrative Cancer Research,Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA 02139, United States.
- Broad Institute of MIT and Harvard, 415 Main Street, Cambridge, MA 02142, United States.
ORCID-Profile: Valerie Lensch, Jeremiah A Johnson, Laura L Kiessling
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- National Science Foundation
- NIH HHS
- National Institutes of Health
Zitieren
APA
Lensch, V., Johnson, J. A., & Kiessling, L. L. (2024). Glycoconjugate vaccines: platforms and adjuvants for directed immunity. Glycobiology, 34(11). https://doi.org/10.1093/glycob/cwae092
Vancouver
Lensch V, Johnson JA, Kiessling LL. Glycoconjugate vaccines: platforms and adjuvants for directed immunity. Glycobiology. 2024;34(11). doi:10.1093/glycob/cwae092
BibTeX
@article{Lensch2024,
author = {Lensch, Valerie and Johnson, Jeremiah A and Kiessling, Laura L},
title = {Glycoconjugate vaccines: platforms and adjuvants for directed immunity},
journal = {Glycobiology},
year = {2024},
volume = {34},
number = {11},
doi = {10.1093/glycob/cwae092}
}
EUVIMED